Skip to content

Study · Randomized controlled trial · n = 39 · 2021

9 results

Subcutaneous adipose tissue composition and function are unaffected by liraglutide-induced weight loss in adults with type 1 diabetes.

Wegeberg AM, Meldgaard T, Baek A, Drewes AM, Vyberg M, Jessen N, Brock B, Brock C

Basic & clinical pharmacology & toxicology5 Mar 2021Cited by 12 (Europe PMC)

PMID33624417 (opens in a new tab)PMCIDPMC8251841 (opens in a new tab)DOI10.1111/bcpt.13575 (opens in a new tab)PepBankPUB-33624417
Read at sourcePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 1 diabetes and polyneuropathy, liraglutide caused weight loss versus placebo (3.38 kg).

    In plain wordsIn adults with type 1 diabetes, liraglutide led to more weight loss than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight change
    Study

    n = 39

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Measurements

    weight loss
    3.38 kg
    liraglutide vs placebo

    Source sentences

    Summary
    In comparison with placebo, liraglutide induced weight loss (3.38 kg, 95% CI -5.29; -1.48, P < 0.001), but did not cause any differences in cell size, distribution of CD163-positive cells, pericellular fibrosis and serum levels of free fatty acids, CD163, leptin or adiponectin (all P < 0.1).
    1 context sentence
    Summary · context
    Thirty-nine adults with type 1 diabetes and polyneuropathy were randomly assigned to 26 weeks of liraglutide or placebo treatment.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with type 1 diabetes and polyneuropathy, liraglutide did not change subcutaneous fat cell size versus placebo.

    In plain wordsIn adults with type 1 diabetes, liraglutide did not change fat cell size compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeAdipocyte cell size
    Study

    n = 39

    Comparator
    Placebo
    Outcome group
    Fat metabolism and adipogenesis · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    In comparison with placebo, liraglutide induced weight loss (3.38 kg, 95% CI -5.29; -1.48, P < 0.001), but did not cause any differences in cell size, distribution of CD163-positive cells, pericellular fibrosis and serum levels of free fatty acids, CD163, leptin or adiponectin (all P < 0.1).
    1 context sentence
    Summary · context
    Thirty-nine adults with type 1 diabetes and polyneuropathy were randomly assigned to 26 weeks of liraglutide or placebo treatment.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with type 1 diabetes and polyneuropathy, liraglutide did not change the distribution of CD163-positive cells in subcutaneous adipose tissue versus placebo.

    In plain wordsIn adults with type 1 diabetes, liraglutide did not change the number of fat-tissue immune cells compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeDistribution of CD163-positive cells in adipose tissue
    Study

    n = 39

    Comparator
    Placebo
    Outcome group
    Inflammation markers · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    In comparison with placebo, liraglutide induced weight loss (3.38 kg, 95% CI -5.29; -1.48, P < 0.001), but did not cause any differences in cell size, distribution of CD163-positive cells, pericellular fibrosis and serum levels of free fatty acids, CD163, leptin or adiponectin (all P < 0.1).
    1 context sentence
    Summary · context
    Thirty-nine adults with type 1 diabetes and polyneuropathy were randomly assigned to 26 weeks of liraglutide or placebo treatment.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with type 1 diabetes and polyneuropathy, liraglutide did not change pericellular fibrosis in subcutaneous adipose tissue versus placebo.

    In plain wordsIn adults with type 1 diabetes, liraglutide did not change scarring around fat cells compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changePericellular fibrosis in adipose tissue
    Study

    n = 39

    Comparator
    Placebo
    Outcome group
    Fat metabolism and adipogenesis · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    In comparison with placebo, liraglutide induced weight loss (3.38 kg, 95% CI -5.29; -1.48, P < 0.001), but did not cause any differences in cell size, distribution of CD163-positive cells, pericellular fibrosis and serum levels of free fatty acids, CD163, leptin or adiponectin (all P < 0.1).
    1 context sentence
    Summary · context
    Thirty-nine adults with type 1 diabetes and polyneuropathy were randomly assigned to 26 weeks of liraglutide or placebo treatment.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with type 1 diabetes and polyneuropathy, liraglutide did not change serum free fatty acids versus placebo.

    In plain wordsIn adults with type 1 diabetes, liraglutide did not change blood free fatty acids compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeSerum free fatty acids
    Study

    n = 39

    Comparator
    Placebo
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    In comparison with placebo, liraglutide induced weight loss (3.38 kg, 95% CI -5.29; -1.48, P < 0.001), but did not cause any differences in cell size, distribution of CD163-positive cells, pericellular fibrosis and serum levels of free fatty acids, CD163, leptin or adiponectin (all P < 0.1).
    1 context sentence
    Summary · context
    Thirty-nine adults with type 1 diabetes and polyneuropathy were randomly assigned to 26 weeks of liraglutide or placebo treatment.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In adults with type 1 diabetes and polyneuropathy, liraglutide did not change serum CD163 versus placebo.

    In plain wordsIn adults with type 1 diabetes, liraglutide did not change the blood level of the immune marker CD163 compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeSerum CD163
    Study

    n = 39

    Comparator
    Placebo
    Outcome group
    Inflammation markers · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    In comparison with placebo, liraglutide induced weight loss (3.38 kg, 95% CI -5.29; -1.48, P < 0.001), but did not cause any differences in cell size, distribution of CD163-positive cells, pericellular fibrosis and serum levels of free fatty acids, CD163, leptin or adiponectin (all P < 0.1).
    1 context sentence
    Summary · context
    Thirty-nine adults with type 1 diabetes and polyneuropathy were randomly assigned to 26 weeks of liraglutide or placebo treatment.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In adults with type 1 diabetes and polyneuropathy, liraglutide did not change serum leptin versus placebo.

    In plain wordsIn adults with type 1 diabetes, liraglutide did not change blood leptin compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeSerum leptin
    Study

    n = 39

    Comparator
    Placebo
    Outcome group
    Adipokines · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    In comparison with placebo, liraglutide induced weight loss (3.38 kg, 95% CI -5.29; -1.48, P < 0.001), but did not cause any differences in cell size, distribution of CD163-positive cells, pericellular fibrosis and serum levels of free fatty acids, CD163, leptin or adiponectin (all P < 0.1).
    1 context sentence
    Summary · context
    Thirty-nine adults with type 1 diabetes and polyneuropathy were randomly assigned to 26 weeks of liraglutide or placebo treatment.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In adults with type 1 diabetes and polyneuropathy, liraglutide did not change serum adiponectin versus placebo.

    In plain wordsIn adults with type 1 diabetes, liraglutide did not change blood adiponectin compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeSerum adiponectin
    Study

    n = 39

    Comparator
    Placebo
    Outcome group
    Adipokines · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    In comparison with placebo, liraglutide induced weight loss (3.38 kg, 95% CI -5.29; -1.48, P < 0.001), but did not cause any differences in cell size, distribution of CD163-positive cells, pericellular fibrosis and serum levels of free fatty acids, CD163, leptin or adiponectin (all P < 0.1).
    1 context sentence
    Summary · context
    Thirty-nine adults with type 1 diabetes and polyneuropathy were randomly assigned to 26 weeks of liraglutide or placebo treatment.
  9. 09HumanRandomized controlled trialMechanism

    In adults with type 1 diabetes and polyneuropathy given liraglutide or placebo, weight loss was not associated with cell size or serum markers.

    In plain wordsIn adults with type 1 diabetes, weight loss was not linked to changes in fat cell size or blood markers.

    Peptide
    Liraglutide
    Outcome
    No significant changeAssociation of weight loss with adipose cell size and serum markers
    Study

    n = 39

    Outcome group
    Fat metabolism and adipogenesis · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Additionally, no associations between weight loss, cell size and serum markers were found (all P > 0.08).
    1 context sentence
    Summary · context
    Thirty-nine adults with type 1 diabetes and polyneuropathy were randomly assigned to 26 weeks of liraglutide or placebo treatment.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.